Cardium Therapeutics Biotech Showcase January 2013 Investor Presentation

1,134 views

Published on

Cardium Therapeutics (NYSE MKT: CXM) is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's newly-acquired To Go Brands® nutraceutical business. The Company's lead commercial product, Excellagen® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands® develops, markets and sells dietary supplements through established regional and national retailers. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.

News and additional information on Cardium is located at www.cardiumthx.com.

Published in: Investor Relations
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,134
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
20
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Cardium Therapeutics Biotech Showcase January 2013 Investor Presentation

  1. 1. Health Sciences & Regenerative Medicine Investor Presentation January 7, 2013Biotech Showcase 2013 Conference The Power of Biology™
  2. 2. Forward Looking Statements This presentation may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Cardium’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Actual results could differ materially from these forward-looking statements for many reasons, including the risks described under "Risk Factors" in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. No guarantee about future results, performance or achievements can be made. Neither Cardium nor its agents intend to update any of the forward-looking statements after the date of this presentation to conform them to actual results or to changes in2013 Cardium Therapeutics, Inc. expectations. 2
  3. 3. Cardium: Focus & Key Skill Set science & medicine 1 4 2 3 regulatory matters2013 Cardium Therapeutics, Inc. & process marketing engineering & finance 3
  4. 4. Portfolio Status Technology Focus Summary Platforms Excellagen® ® Tissue Engineering: Wound Care Formulated Collagen FDA 510(k) and DNA-Activated Clearance Matrices for Wound Initial Product & Orthopedic Repair Introduction Underway Portfolio of Generx® ® Cardiovascular Growth [Ad5FGF-4] Factor Biologics “ASPIRE” Phase 3 Acquired from Registration Study for Schering AG International Markets MedPodium2013 Cardium Therapeutics, Inc. Health Sciences Brand Platform: Organic Mixes, Nutraceuticals & Dietary Supplements 4
  5. 5. Strategic Partner-Enabled Opportunities Technology Focus Summary Platforms Planning small, cost-effective Phase 2b/3 study to confirm accelerated DNA-based Tissue engineering and wound healing. Next generation product regenerative medicine platform candidate represents first product and DNA-Activated matrices extension from the FDA-cleared Excellagen for wound repair & orthopedic technology. Plug-n-Play Phase 3 biologic repair and restoration product candidates offer considerable economic value opportunity Medical analytics and Millions of cancer survivors remain e-commerce platform of uninsurable by traditional life insurance algorithms and medical-based underwriting standards. Cardium is social media focused programs developing new scalable methodologies to support specialized survivable designed to assess relative survival risks risk life insurance underwriting for life insurance companies to address for cancer patients, cancer this significant under-appreciated survivors and patients with economic opportunity chronic medical diseases2013 Cardium Therapeutics, Inc. MedPodium Health Sciences Leverage TO GO BRANDS® established in-house brand platform: infrastructure, distribution capabilities and organic mixes, nutraceuticals retail network to support external product and dietary supplements acquisitions and strategic partnerings Distribution & Logistics Platform 5
  6. 6. Investment Highlights Capital-efficient, asset-based, business strategy focused on finding “diamonds in the rough” and leveraging research and development investments by big pharma, venture and institutional investors Strategy intended to provide a diversified and more balanced portfolio of risk/return opportunities Excellagen® Advanced Wound Care Management Platform: FDA 510(k) clearance for U.S. marketing and sales International CE mark registration targeted for 1Q/2013 Initial focus on diabetic foot ulcers Consistent with business strategy, support initial market introduction, seed the market, then monetize through strategic partnerships and distribution deals in U.S. and international markets Strategic partnering process underway CPT® code reimbursement in place (for surgical debridement using Excellagen) CMS and private payor reimbursement plan progressing Recently announced marketing and sales agreement with Academy Medical for U.S. Government installations including Veterans Administration and military hospitals Generx® Global Cardiovascular Platform: International cost-efficient “ASPIRE” Phase 3 / Registration Study underway Study Design: 100 patients with SPECT imaging efficacy endpoint Initial medical condition: Cardiac Microvascular Insufficiency (CMI) for patients with myocardial ischemia with symptomatic chronic stable angina due to coronary artery disease MedPodium® In-House Brand Platform: Portfolio of premium, science-based, easy-to-use nutraceuticals designed to promote personal health and well being for todays active, informed and professional lifestyles Recently announced the acquisition of To Go Brands® to support logistical infrastructure to accelerate revenue Cardium Werks™: Portfolio of strategic partner-enabled product and platform opportunities that have been internally developed based on Cardium’s unique skill set, capabilities and technology Genedexa™: a Phase 2b/3 DNA-based wound healing product candidate representing the first product extension from the FDA cleared Excellagen technology LifeAgain™: a medical analytics and e-commerce platform of algorithms and medical-2013 Cardium Therapeutics, Inc. based social media focused programs To Go Brands®: leverage established logistics and retail platform to market, distribute and sell new products based on internal development and external acquisitions Alternative independent financing strategies may be utilized to support these opportunities Key Investor Metrics: No outstanding debt, substantial trading liquidity, continuing news flow expected from product platforms and other opportunities under consideration Current capital structure provides for significant economic upside potential as CXM executes its asset-based business strategy Capital-efficient ATM Shelf Registration in place 6
  7. 7. Excellagen ® Pharmaceutically- Formulated Collagen (2.6%) Acellular Biological Modulator Excellagen is an FDA-cleared syringe-based flowable topical gel that promotes the activation of the healing process for the treatment of dermal wounds. It is designed to accelerate granulation tissue growth in non-healing wounds and activates platelets, triggering the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biologic mediator of wound healing.2013 Cardium Therapeutics, Inc. It is indicated for the treatment of a broad array of wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds. 7
  8. 8. ® Excellagen® Summary & Commercialization Status Excellagen is the best-in-class acellular Post-marketing in vitro study supports biological modulator designed to platelet activation triggering the release accelerate the growth of granulation of endogenous PDGF, an important tissue for wound healing wound healing mediator FDA 510(k) clearance for treatment of a Market introduction underway to KOL broad array of dermal wounds physicians Initial medical focus: Diabetic Foot Ulcers Unified packaging, web site and DTC positioning complete Competitively positioned via aseptically manufactured, pharmaceutically- Selected as 2012 Top 10 Innovation in formulated collagen, flowable syringe- Podiatry by Podiatry Today magazine based format, ease and simplicity of use Matrix multi-center clinical study shows Uses controlled temperature storage significant tissue growth and positive (2-8 C) to maintain bio-activity2013 Cardium Therapeutics, Inc. wound closure versus control at 12 weeks based on average of 1.6 treatments Outsourced supply chain fully operational including U.S. cold chain Matrix Excellagen clinical study data distributor: Smith Medical Partners published in peer-reviewed journal 8
  9. 9. ® Excellagen® Summary & Commercialization Status Medical Advisory Board established; Enabling product extensions for new and sampling and case studies advancing innovative regenerative medicine product formulations International CE mark registration in progress, (expected 1Q/2013) Initial broad labeling allows for conduct of cost-efficient, post-marketing studies New product CMS reimbursement for specifically narrowed and higher submissions completed economic value product labeling claims Excellagen uses subject of patent Current CPT® procedure codes cover use applications with debridement for DFUs In discussions with potential strategic Fully validated cGMP and ISO-certified partners to support marketing and sales collagen manufacturing process and into four vertical markets: (1) podiatry; (2) facilities dermatology; (3) wound care centers and hospitals; and (4) government healthcare2013 Cardium Therapeutics, Inc. Aseptic manufacturing process utilizes system markets cost-effective, single-use, disposable bio- process components and avoids Recently announced marketing and sales potentially inactivating terminal agreement with Academy Medical for U.S. sterilization government medical providers 9
  10. 10. Excellagen: Integration into the Practice of Medicine Stage I Stage II Stage III Normal Stalled Chronic Healing Response Healing Response Non-Healing (> 6 weeks) Debridement, Debridement DermaGraft® Excellagen® & Dressing Apligraf® & Dressing NPWT Diabetic Diabetic Diabetic Foot Ulcers Foot Ulcers Foot Ulcers Excellagen is an acellular biological modulator. It is comprised of flowable fibrillar Type I bovine collagen gel that is configured into a staggered2013 Cardium Therapeutics, Inc. quaternary array of three-dimensional triple helical, telopeptide-deleted tropocollagen molecules. This configuration provides a structural scaffold for cell adhesion, migration and proliferation, and a bioactive substrate for platelet activation and release of essential growth factors including platelet- derived growth factor (PDGF). 10
  11. 11. ® Excellagen®: Technology & Formulation High Molecular Weight Fibrillar Type I Bovine Collagen FDA-Cleared, Specialized Functional Aseptic Process & Pharmaceutical Clinical Study Data Excipients Published in Peer Review Journal2013 Cardium Therapeutics, Inc. Simple | Flowable | Ready to Use Once Weekly Treatment 11
  12. 12. ® Excellagen®: Advanced Wound Care Management Platform Refined custom formulated engineered for debridement procedures fibrillar Type I bovine collagen High molecular weight Biocompatible, physiologic pH Pre-filled, ready to use syringes Simple and easy: no thawing or mixing Flowable: no staples or sutures Viscosity optimized for complete, dripless wound coverage Treatment at only one week intervals Excellagen has been shown to activate Refrigerated storage required: human platelets, triggering the release of Cold Chain logistics partner: Smith Medical Platelet-Derived Growth Factor (PDGF) For professional use only; established Formulated collagen (2.6%) accelerates2013 Cardium Therapeutics, Inc. standard CPT® procedure codes may growth of granulation tissue immediately apply when used with debridement following treatment compared to standard of care control arm (n=45 / P=0.018) Each kit contains four single-use syringes based on Matrix Clinical Study. Blume et containing 0.5cc of Excellagen topical gel al., Wound Rep. Reg. 19: 302-308 (2011). and four sterile flexible applicators 12
  13. 13. ® Excellagen: Next Generation Product Format First Generation Next Generation2013 Cardium Therapeutics, Inc. 0.5cc/syringe 0.5cc/ampule Syringe Format Ampule Format 13
  14. 14. Excellagen® Treatment: ® Diabetic Foot Ulcers 1 2 3 4 Debride Treat Bandage Offload2013 Cardium Therapeutics, Inc. www.excellagen.com 14
  15. 15. In Vitro Research Study Data Excellagen Activates the Healing Process Activated Platelet Release of PDGF2013 Cardium Therapeutics, Inc. The Power of Biology™ 15
  16. 16. ® Excellagen: Post-Marketing Case Studies Acellular Biological Modulator 1 2 1 2 3 4 3 4 42 Days Stalled: 4 Excellagen® Applications 240 Days Stalled: 5 Excellagen® Treatments2013 Cardium Therapeutics, Inc. 49 Days to Closure 63 Days to Closure Excellagen® Pharmaceutically-Formulated Collagen Topical Gel Accelerates Healing Rate Immediately After Application in Patients with Diabetic Neuropathic Foot Ulcers1 1 Blume et al., Wound Rep. Reg. 19: 302-308 (2011). 16
  17. 17. ® Excellagen: Tissue Regeneration Case Studies Acellular Biological Modulator % Area Reduction % Area Reduction 100 100 Case 2 Case 1 Zimny Pfohl Zimny Pfohl 80 80 % Area Reduction % Area Reduction 60 60 40 40 Healing Prediction Healing Prediction Study Baseline1 Study Baseline1 20 20 0 0 0 1 2 3 4 5 6 7 8 9 10 11 12 0 1 2 3 4 5 6 7 8 9 10 11 12 Weeks Weeks 42 Days Stalled: 4 Excellagen® Applications 240 Days Stalled: 5 Excellagen® Treatments2013 Cardium Therapeutics, Inc. 49 Days to Closure 63 Days to Closure Excellagen® Pharmaceutically-Formulated Collagen Topical Gel Accelerates Healing Rate Immediately After Application in Patients with Diabetic Neuropathic Foot Ulcers2 1Healing Times and Prediction of Wound Healing. Zimny S. and Pfohl M. Exp. Clin. Endocrinol Diabetes 113:90-93 (2005). 2Blume et al., Wound Rep. Reg. 19: 302-308 (2011). 17
  18. 18. ® Matrix: Tissue Regeneration MATRIX Multi-Center Controlled & Randomized Metrics of Tissue Growth Wound Study Wound Size Reduction (n = 47) Bio-Metric Pharmaceutically- Standard Pre-Specified Matrix Formulated Collagen of Care Percent Protocol Assessment: 2.6% Improvement One Excellagen Treatment (n = 31) (n = 16) Average Wound Size 3.0 cm2 3.0 cm2 X Matrix Non-Healing Ulcers: Excellagen vs. Control1 + 208% Wound Size (Area) 37% 12%1 (p = 0.018) Reduction @ Week 1 Cumulative Wound Size (Area) + 104% 49% 24%1 Reduction @ Week 2 (p = 0.032)2013 Cardium Therapeutics, Inc. Excellagen vs. Healing Prediction Study2 Wound Size (Area) 37% 8%2 + 362% Reduction @ Week 1 Cumulative Wound Size (Area) 49% 15%2 + 227% Reduction @ Week 2 1Blume et al., Wound Rep. Reg. 19: 302-308 (2011). 2Healing Times and Prediction of Wound Healing. Zimny S. and Pfohl M. Exp. Clin. Endocrinol Diabetes 113:90-93 (2005). 18
  19. 19. Commercial Business: Vertical Marketing & Sales Opportunities ® U.S. Government Hospital, including Wound Healing Veterans Podiatry Dermatology Centers & Administration Focus Focus Long-Term & military Facilities hospitals2013 Cardium Therapeutics, Inc. International Markets 19
  20. 20. ® Excellagen: Strategic Fit with Current Advanced Wound Healing Products Treatments for Diabetic Foot Ulcers Advanced Wound Care Advanced Wound Healing Bioresorable Scaffold with Acellular Biological Modulator Metabolically Active Living Cells Lower Priced Higher Priced Professional Use Professional Use Adjunct to Surgical Dermal Engraftment Debridement Standard of Care Specific Therapeutic Use Claims for Treatment of Broad Product2013 Cardium Therapeutics, Inc. Diabetic Foot Ulcers Only Use Applications Cold Chain Distribution Cold Chain Distribution Tissue Regeneration Dermagraft® is a Registered Trademark of Advanced BioHealing, a subsidiary of Shire PLC. 20
  21. 21. ® Excellagen: Strategic Fit with Current Advanced Wound Healing Products Regenerative Medicine Advanced Wound Care Platelet Growth Factor Activation FDA-Cleared Professional Use Adjunct to Platelet-2013 Cardium Therapeutics, Inc. Rich Plasma Therapy Broad Product Autologous Platelet-Rich Therapy Use Applications 21
  22. 22. ® Excellagen U.S. Market Opportunities: Beyond Diabetic Foot Ulcers Medical Condition Wound Type Incidence Venous Ulcers 1,625,000 Illness Arterial ulcers 1,725,000 Diabetic foot ulcers 1,260,0001 Immobility Pressure Ulcers 2,500,000 Surgical Wounds: Major 36,000,000 Surgical Surgical Wounds: Moderate/Minor 31,000,000 Mohs Surgery 850,000 Burn injuries 1,285,000 Trauma Amputations 150,0002013 Cardium Therapeutics, Inc. Traumatic Wounds/Lacerations2 16,250,000 TOTAL 92,645,000 Source: Medtech Insight 1Source: American Diabetes Association 2Traumatic wounds/lacerations consist of open wounds (approx. 8.7 million), superficial wounds (approx. 1.7 million), and contusions (approx. 5.8 million) seen in emergency rooms. 22
  23. 23. Excellagen® Medical Opportunity Chronic Diabetic Pressure Foot Ulcers Ulcers ® Other Wounds: Including Venous Surgical Ulcers & Burns2013 Cardium Therapeutics, Inc. Activate the Healing Process 23
  24. 24. ® Excellagen® Case Study: Venous Leg Ulcer Arthur Tallis, DPM, FACFAS Phoenix, AZ Day 56: After 4 applications of Excellagen Day 1: Pretreatment (Unna boot worn from Day 27-56) Patient Demographic Data2013 Cardium 2013 Cardium Therapeutics, Inc. Age 62 Sex Male Therapeutics, Inc. General Health Status Venous Insufficiency Wound Duration 13 Months Prior to Treatment Prior Therapies Anticoagulants, Four-layer compression dressing 24
  25. 25. ® Excellagen® Case Study: Mohs Surgery “Excellagen gel proved to be an outstanding healing agent for an extensive Mohs surgery wound. It is an economical alternative to costly skilled nursing care.” Steven Smith, MD, Wellesley, MA Day 14: After One Day 22: After Two Day 49: After Three Excellagen Treatment Excellagen Treatments Excellagen Treatments. Full Re-Epithelization Patient Demographic Data 2013 Cardium Therapeutics, Inc. Age 75 Sex Male2013 Cardium Therapeutics, Inc. Nursing home resident with dementia. Mohs surgery performed on General Health Status recurrent squamous cell carcinoma. Repair with skin grafting not feasible due to expectation that patient would disturb surgical dressings. Mohs Surgical Site Left-Posterior Ear/Mastoid Excellagen Treatment 25 Days 4, 14, and 22 post-surgery
  26. 26. ® Excellagen® Case Study: Pressure Ulcer “Noticed healing accelerated after first week- I was pleasantly surprised. I’m very pleased” Curtis Long, DPM, Walla Walla, WA 5/21/2012: Wound Area 3.5 cm2. 7/16/2012: Complete Wound Sharp Debridement Followed Closure at 8 weeks After Single by Excellagen Application Application of Excellagen Patient Demographic Data Age 682013 Cardium 2013 Cardium Therapeutics, Inc. Sex Male Therapeutics, Inc. General Health Status Obese, Wheelchair-Dependent, Type II Diabetes Wound Location Left Plantar Heel- formed at pressure point (foot rest of wheelchair) Wound Duration 16 Weeks Prior to Treatment Prior Therapies 26 Debridement, Hydrophilic Wound Dressing, Pressure-Relieving Padding
  27. 27. Advanced Modality Cost Comparison for Wound Therapies $20,000 Estimated costs associated with full 12 weeks of DFU treatment including physician and nursing time, facility charges, treatment costs and associated standard of care. $15,000 $13,900 $11,600 $10,000 $8,100 $5,000 $3,590 $600 $02013 Cardium Therapeutics, Inc. Excellagen® KCI Negative Apligraf4 Dermagraft5 Topical Gel1 GraftJacket Pressure Xpress Gel®2 Wound Therapy3 1Excellagen® assumes 4 treatments. 2Assumes 2 treatments. 3Based on 16 weeks of DFU treatment of NPWT in accordance with RCT. 4Based on an average of 4 surgical applications (per Policy up to 5 surgical applications are allowed). 5Based on an average of 6 surgical applications (per Policy up to 8 applications are allowed). 27
  28. 28. Excellagen: Enabling Delivery Platform Small Peptides Molecule Drugs ® Anti- Conditioned microbials Cell Media2013 Cardium Therapeutics, Inc. DNA-Based Pluripotent Biologics Stem Cells 28
  29. 29. CardiumWerks™: Genedexa Next Generation DNA-Based Wound Healing Therapeutic Excellagen Technology Platform Adenovector DNA-Based Phase 1 & 2 Delivery (Ad5) Clinical Studies Manufacturing PDGF-BB Know-How Growth Factor & Expertise Gene • Planning CXM-Supported Small2013 Cardium Therapeutics, Inc. (10-20 Patient) Confirmatory Phase 2b/3 Clinical Study • Strategic Partnered-Enabled Phase 3 Product Opportunity 29
  30. 30. Generx ® [Ad5FGF-4] DNA-Based Angiogenic Therapy Interventional cardiology-focused product candidate that is being developed for a medical condition termed Cardiac Microvascular Insufficiency (CMI) in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to coronary artery disease. Patients with CMI have had an insufficient angiogenic response to their current disease2013 Cardium Therapeutics, Inc. state and may benefit from a therapy to biologically enhance cardiac perfusion through the facilitation of collateral vessel formulation. This condition is diagnosed by SPECT imaging, and other catheter-based diagnostic techniques. 30
  31. 31. Coronary Artery Disease Disease-Induced Angiogenic Response2013 Cardium Therapeutics, Inc. OFF ON 31
  32. 32. Beneficial Effects of a Disease-Induced Angiogenic Vascularization Summary Research “A well-functioning coronary collateral circulation saves lives in patients with chronic stable coronary artery disease.”2013 Cardium Therapeutics, Inc. From Meier et al. Circulation 2007; 116:975-83. 32
  33. 33. Generx®: Historical Perspective Collateral Schering AG Cardium Commercial Therapeutics As Strategic Partner Therapeutics International (NASDAQ) with Collateral Formed to Development Therapeutics Acquire Activities University of Technology from Schering Acquires California Schering / Bayer Collateral in 2002 Russia San Diego FDA Phase 3 Clearance for $160 Million with Fast Track Status Brazil Discovery, Licensing & Phase 3 Clearance India Phase 1/2 to and Initial for Registration Study Phase 2b/3 in Russia Preclinical Studies 1996 1997 - 2005 2005 - Present Current Status2013 Cardium Therapeutics, Inc. 33
  34. 34. Generx® [Ad5FGF-4] Clinical & Commercial Development Activities Cardium Innovations • Expanded target coronary artery disease patient population AGENT 1–4 • Established new quantitative ASPIRE primary efficacy endpoint using Phases 1 & 2/3 SPECT imaging Phase 3 Clinical Studies Clinical Study • New balloon catheter-based delivery techniques to leverage Treatment: Stable Cardium’s transient ischemia Treatment: Patients discoveries to boost cell Angina for Patients with with Myocardial transfection “Refractory” Coronary Ischemia Due to • Developed new “bio-assay” Artery Disease production batch release assay Coronary Artery Disease that measures angiogenic Primary Endpoint: response to Generx Primary Endpoint: ETT Improvement • Five-year real-time product RPDS Improvement as2013 Cardium Therapeutics, Inc. stability (at -70°C) confirmed Measured by SPECT 650 Patients at • Simplified and standardized 100 Medical Centers new cath lab product 100 Patients preparation techniques 34
  35. 35. ® Generx®: Current Global Clinical Study Status International Markets U.S. Market Elements (Initially Russian Federation) (AWARE) (ASPIRE) Generx® [Ad5FGF-4] CardioNovo [Ad5FGF-4] Product (alferminogene tadenovec) (alferminogene tadenovec) FDA Clearance Phase 3 RHA Cleared Phase 3 / Clinical Status (with Fast Track Status) Registration Study 100 Men & Women 300 Women Multi-Center, Multi-Center, Randomized, Clinical Study Population Randomized, Placebo- Controlled Parallel-Group Controlled Patient Population Patient Population Anti-Angina for Refractory Myocardial Ischemia as a Patients who are not Optimal Treatment Option for Patients Proposed Medical Indication Candidates for Angioplasty / Considering Angioplasty / Stents & Bypass Surgery Stents & Bypass Surgery Improvement in Reversible2013 Cardium Therapeutics, Inc. Improvement in Exercise Clinical Endpoint Time Based on Treadmill Perfusion Deficit Based on SPECT Imaging Pending Completion Clinical Study Status Initiated 2012 of International Studies 35
  36. 36. Potential Therapeutic Positioning: Generx® / Cardionovo® (PTCA) Percutaneous Traditional Transluminal Drug Coronary Therapy Angioplasty & Stents Coronary Artery Disease Generx® (CABG) Non-Surgical Coronary DNA-Based Artery Bypass Angiogenic2013 Cardium Therapeutics, Inc. Surgery Therapy 36
  37. 37. Generx® [Ad5FGF-4] Proprietary Intracoronary Administration of DNA-Based Cardiovascular Growth Factor Therapeutic Non-surgical delivery by intracoronary administration by interventional cardiologist during an angiogram procedure Utilizes standard balloon catheter which can be easily integrated into diagnostic angiogram procedures or with other2013 Cardium Therapeutics, Inc. percutaneous coronary interventions New induced transient ischemia / reperfusion techniques are designed to enhance DNA uptake and expression in the heart 40% administered to right coronary circulation and 60% to left coronary circulation 37
  38. 38. Generx® [Ad5FGF-4] Catheter-Based Angiogenic Intracoronary Delivery Microvascular Circulation2013 Cardium Therapeutics, Inc. 38
  39. 39. The Therapeutic Process of Cardiac Microvascular Angiogenesis Generx has been evaluated in studies of over 650 patients (including 450 Generx-treated patients) in four multi-center, double-blind, placebo-controlled SPECT Imaging clinical studies at 100 medical centers. Generx is the most clinically advanced DNA-based cardiovascular angiogenic growth factor therapeutic in the world. One-Time Treatment DNA-Based Delivery Generx [Ad5FGF-4]2013 Cardium Therapeutics, Inc. (alferminogene tadenovec) Angiogenic Response AGENT-2 - Representative Generx-treated patient: 77% improvement in cardiac perfusion at 8 weeks equivalent to bypass surgery and PCI (angioplasty/stenting) at one year. 39
  40. 40. Effect of Chronic Angina Treatment with Ranexa and Single Intracoronary Administration of Generx (Ad5FGF-4) on ETT Duration at 12 Weeks (Difference from Placebo) 100 * ETT * P > 0.05 vs. placebo Mean change from Baseline (sec) 75 Generx 50 One Time Non-Surgical Angiogenic Therapy * 25 Ranexa2013 Cardium Therapeutics, Inc. Chronic Anti-Anginal Drug 1000 mg Daily 0 Baseline ETT (sec): 300 Baseline ETT (sec): 470 % increase + 25% % increase + 5% (n = 30) (n = 255) 40
  41. 41. Technology Platform: Non-Surgical DNA-Based Angiogenic Therapy Methods of Intracoronary DNA-Based Angiogenic Therapy X Adenovirus DNA-Based Manufacturing Delivery (Ad5) Know-How & Expertise Angiogenic Growth Factor (FGF-4)2013 Cardium Therapeutics, Inc. Generx® [Ad5FGF-4] (alferminogene tadenovec) 41
  42. 42. Generx® (alferminogene tadenovec) DNA-Based Adenovector Cassette Demonstrated CV Safety Database with FDA Established FDA Manufacturing Standards High Cardiac Transfection Levels due to a Binding Affinity with CAR Receptors and Enhanced by Ischemia Transient Expression - Does Not Integrate into Adenovector construct Host Genome Carries the FGF-4 Gene for Cardiac Delivery Manufacturing in High Titer Easily Manipulated Research Studies: Coronary Relatively Low Cytotoxity2013 Cardium Therapeutics, Inc. Intracoronary Administration Extraction Rate Pre-Clinical Porcine Study Mutagenesis Improbable 98% (mean) Giordano et al. Nat Med 1996;2:(5):534 Very Favorable Phase 1/2 Clinical Study – AGENT Trial Manufacturing Cost 87% (median) Grines et al. Circulation 2002;105:1291 42
  43. 43. Generx Dose Response Bioactivity Assay Visualization of the Angiogenic Process by Endothelial Tube Formation 1ng/mL 2ng/mL 4ng/mL 8ng/mL Representative Images (T=13.5 days) of rhFGF-4 stimulation of angiogenic networks in the Essen BioScience HUVEC Tube Formation Assay. E, 1ng/mL rhFGF-4 induced HUVEC clustering as well as a small amount of tube formation. F, 2ng/mL rhFGF-4 induced clusters and tube formation. G, 4ng/mL rhFGF-4 initiated HUVEC differentiation into longer tubes and more complex networks, as observed by the increase in branching. H, 8ng/mL rhFGF-4 stimulate significant tube and network formation.2013 Cardium Therapeutics, Inc. 43
  44. 44. MEDPODIUM Health Sciences Science-Based Lifestyle Solutions2013 Cardium Therapeutics, Inc. Cardium (CXM) announces acquisition of To Go Brands® 44
  45. 45. To Go Brands® develops markets and sells a portfolio of über healthy, science-based, great tasting, anti-oxidant rich, super-charged phytonutrients and nutraceuticals supplements in an array of easy use formats, including drink mixes, chews, powders and capsules, to empower busy lifestyles in today’s fast-paced, teach driven world. These products are sold through the company’s web-based store and food, drug and mass channels at retailers.2013 Cardium Therapeutics, Inc. Go Active! | Go Healthy! | Go Trim! 45
  46. 46. Cardium: Expanded Health Sciences Platform2013 Cardium Therapeutics, Inc. 46
  47. 47. Cardium Acquisition: To Go Brands® Founded in 2007, To Go Brands is a privately-held San Diego-based company that develops, markets and sells a portfolio of over 25 products, including nutraceutical powder mixes, supplements and chews to support healthy lifestyles. Acquisition is focused on accelerating the growth and development of Cardium’s in-house MedPodium brand platform. This transaction provides: portfolio of marketed products established logistics and distribution capabilities a website e-commerce platform experienced management team with key contacts and a track record of developing and placing new and innovative health and nutraceutical products into the mass, food and drug retail channels revenue platform with growth potential.2013 Cardium Therapeutics, Inc. To Go Brands will coordinate Cardium’s health sciences brand platform including MedPodium Nutra-Apps® product line, as well as the strategic investment in SourceOne Global Partners. 47
  48. 48. To Go Brands®: Current Retail Platform2013 Cardium Therapeutics, Inc. 48
  49. 49. To Go Brands®: Energy & Weight Management2013 Cardium Therapeutics, Inc. 49
  50. 50. To Go Brands®: Product Portfolio2013 Cardium Therapeutics, Inc. 50
  51. 51. To Go Brands®: Product Formats Stick Packs Scoop2013 Cardium Therapeutics, Inc. Chews 51
  52. 52. To Go Brands®: Spotlight on Product Portfolio2013 Cardium Therapeutics, Inc. 52
  53. 53. To Go Brands®: Portfolio Intersection2013 Cardium Therapeutics, Inc. 53
  54. 54. Strategic Partner-Enabled Opportunities Technology Focus Summary Platforms Planning small, cost-effective Phase 2b/3 study to confirm accelerated DNA-based Tissue engineering and wound healing. Next generation product regenerative medicine platform candidate represents first product and DNA-Activated matrices extension from the FDA-cleared Excellagen for wound repair & orthopedic technology. Plug-n-Play Phase 3 biologic repair and restoration product candidates offer considerable economic value opportunity Medical analytics and Millions of cancer survivors remain e-commerce platform of uninsurable by traditional life insurance algorithms and medical-based underwriting standards. Cardium is social media focused programs developing new scalable methodologies to support specialized survivable designed to assess relative survival risks risk life insurance underwriting for life insurance companies to address for cancer patients, cancer this significant under-appreciated survivors and patients with economic opportunity chronic medical diseases2013 Cardium Therapeutics, Inc. MedPodium Health Sciences Leverage TO GO BRANDS® established in-house brand platform: infrastructure, distribution capabilities and organic mixes, nutraceuticals retail network to support external product and dietary supplements acquisitions and strategic partnerings Distribution & Logistics Platform 54
  55. 55. Cardium: Focus & Key Skill Set science & medicine 1 4 2 3 regulatory matters2013 Cardium Therapeutics, Inc. & process marketing engineering & finance 55
  56. 56. CardiumWerks™: Genedexa Next Generation DNA-Based Wound Healing Therapeutic Excellagen Technology Platform Adenovector DNA-Based Phase 1 & 2 Delivery (Ad5) Clinical Studies Manufacturing PDGF-BB Know-How Growth Factor & Expertise Gene • Planning CXM-Supported Small2013 Cardium Therapeutics, Inc. (10-20 Patient) Confirmatory Phase 2b/3 Clinical Study • Strategic Partnered-Enabled Phase 3 Product Opportunity 56
  57. 57. Genedexa DNA-Based Adenovector Cassette Demonstrated Phase 1/2 Safety Data with FDA No Cytotoxicity Observed Established FDA Manufacturing Standards Manufacturing in High Titer Adenovector construct Favorable Manufacturing Carries the PDGF-B Gene Costs Research Studies: High Dermal Transfection Topical Administration Levels2013 Cardium Therapeutics, Inc. Preclinical Efficacy Studies Transient Expression Doukas et al; Human Gene Therapy 2001 12:783-798 Gu et al; Wounds 2004 16:34-41 Mutagenesis Improbable Toxicology and Biolocalization Gu et al; Molecular Therapy 2004 9:699-711 57
  58. 58. Genedexa: Stimulates Increased Granulation Tissue Collagen without Ad5Luc/Collagen Platelet Activation Granulation Tissue Growth Synergistic2013 Cardium Therapeutics, Inc. Effect of Collagen and Ad5PDGF-BB (saline) Genedexa™ Ad5PDGF-B Cartilage removed Day 7, 20x, Ad5PDGF-B 2.3x109 vp, Ad5Luc 6x109 vp Doukas et al. Hum Gene Therapy, 2001 Vol 12(7) 58
  59. 59. Genedexa [Ad5PDGF-B] Induces Increased Granulation Tissue and Re-Epithelialization Pre-Clinical Studies 10 1.0 * P = 0.009 * * P = 0.001 SD * SD Granulation Tissue Area (mm2) Epithelium Area (mm2) 5 0.52013 Cardium Therapeutics, Inc. 0 0.0 Collagen AdPDGF-B Collagen AdPDGF-B w/o Platelet w/o Platelet 4E + 9 PN AdPDGF-B 2.6% Collagen gel Activation Activation N=6 Day 8 59
  60. 60. 2013 Cardium Therapeutics, Inc.
  61. 61. Estimated Number of US Cancer Survivors Form of Disease Current 2012 Projected 2022 Prostate 2,778,630 3,922,600 Breast 2,971,610 3,786,610 Thyroid 436,590 609,690 Testis 230,910 295,590 Melanoma 977,250 1,324,260 Hodgkins Lymphoma 534,950 713,810 Other 5,670,060 7,347,4402013 Cardium Therapeutics, Inc. Total 13.6 Million 18.0 Million Sources: Data Modeling Branch, Division of Cancer Control and Population Sciences, National Cancer Institute; American Cancer Association. 61
  62. 62. Percentage of U.S. Households Owning Individual Life Insurance Despite all time low priced web-based life insurance premiums, policy ownership is at a 26-year low2013 Cardium Therapeutics, Inc. Source data: LIMRA’s 2010 Life Ownership study. 62
  63. 63. Percentage of Adults Admitting “I Need More Life Insurance” = 117 million adults2013 Cardium Therapeutics, Inc. Source data: U.S. Census – 2010; LIMRA’s 2010 Life Ownership study. 63
  64. 64. 2013 Cardium Therapeutics, Inc.64

×